Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) CFO Mark J. Vignola sold 9,059 shares of Terns Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $5.80, for a total value of $52,542.20. Following the transaction, the chief financial officer now owns 74,752 shares in the company, valued at $433,561.60. This trade represents a 10.81 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Terns Pharmaceuticals Price Performance
Shares of NASDAQ:TERN opened at $5.63 on Wednesday. The company’s 50-day moving average price is $6.32 and its two-hundred day moving average price is $7.40. Terns Pharmaceuticals, Inc. has a one year low of $4.32 and a one year high of $11.40. The stock has a market capitalization of $478.21 million, a PE ratio of -4.77 and a beta of -0.31.
Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.05. On average, analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Report on Terns Pharmaceuticals
Hedge Funds Weigh In On Terns Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in TERN. Bank of New York Mellon Corp raised its position in Terns Pharmaceuticals by 56.8% during the second quarter. Bank of New York Mellon Corp now owns 176,673 shares of the company’s stock worth $1,203,000 after acquiring an additional 64,018 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Terns Pharmaceuticals by 50.3% during the 2nd quarter. Rhumbline Advisers now owns 88,641 shares of the company’s stock worth $604,000 after purchasing an additional 29,659 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Terns Pharmaceuticals by 17.7% in the 2nd quarter. American Century Companies Inc. now owns 64,119 shares of the company’s stock valued at $437,000 after purchasing an additional 9,635 shares during the period. Dimensional Fund Advisors LP lifted its stake in Terns Pharmaceuticals by 9.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 371,892 shares of the company’s stock valued at $2,534,000 after purchasing an additional 31,875 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Terns Pharmaceuticals during the second quarter worth about $596,000. 98.26% of the stock is owned by institutional investors.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Read More
- Five stocks we like better than Terns Pharmaceuticals
- Why Are Stock Sectors Important to Successful Investing?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Energy and Oil Stocks Explained
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Golden Cross Stocks: Pattern, Examples and Charts
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.